Clover Health Investments, Corp (CLOV) Stock Analysis

Q: What is the CLOV stock price target?

Take-profit $2.59 (-1.0% upside). Prior stop was $2.43.

Q: What are the risks of investing in CLOV?

Target reached (-8.4% upside); Quality below floor (1.5 < 4.0); Target reached (-8.4% upside); Quality below floor (1.5 < 4.0).

Q: Is CLOV overvalued or undervalued?

Clover Health Investments, Corp trades at a P/E of N/A (forward 28.7). TrendMatrix value score: 7.6/10. Overall verdict: Sell.

Q: What do analysts say about CLOV?

10 analysts cover CLOV with a consensus score of 3.8/5. Average price target: $3.

Recovery setup

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Healthcare Plans

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $2.61: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality.

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for... Read more

$2.61-1.0% A.UpsideScore 5.4/10#3 of 11 Healthcare Plans

Stop $2.43Target $2.59(resistance)A.R:R -0.6:1

Analyst target$2.82+7.9%3 analysts

$2.59our TP

$2.61price

$2.82mean

Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Target reached (-8.4% upside)

Quality below floor (1.5 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)28.7

Mkt Cap$1.4B

EV/EBITDA-14.5

Profit Mgn-4.4%

ROE-26.3%

Rev Growth44.7%

Beta2.25

DividendNone

Rating analysts10

Quality Signals

Piotroski F3/9

Options Flow

P/C0.73neutral

IV104%elevated

Max Pain$1-80.8% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.615%1.14

Quality1.515%0.22

Growth10.015%1.50

Momentum5.810%0.58

Sentiment5.410%0.54

Insider Activity3.810%0.38

Peer Rank4.310%0.43

Technical Setup1.75%0.09

Risk Profile3.45%0.17

Catalyst7.55%0.38

Overall (Σ contributions)5.42

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Unprofitable operations — net margin -4.4%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

3.3

Moat

5.0

Current Ratio

5.4

Cash-burning: FCF -2% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance

0.3

Bollinger

1.4

52w Position

3.3

GatesA.R:R -0.6=NEGATIVEEARNINGS PROXIMITY 6d<=7dDeath cross (50MA < 200MA)Momentum 5.8>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive

RSI

84 · Overbought

↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $1.66Resistance $2.64

Price Targets

A.Upside-0.8%

A.R:R-0.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-8.4% upside)

! Quality below floor (1.5 < 4.0)

! Negative risk/reward — downside exceeds upside

Earnings

1/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is CLOV stock a buy right now?

Sell if holding. Engine safety override at $2.61: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality. Chart setup: Death cross but MACD improving, RSI 84. Prior stop was $2.43. Score 5.4/10, moderate confidence.

What is the CLOV stock price target?

Take-profit target: $2.59 (-1.0% upside). Prior stop was $2.43. Stop-loss: $2.43.

What are the risks of investing in CLOV?

Target reached (-8.4% upside); Quality below floor (1.5 < 4.0).

Is CLOV overvalued or undervalued?

Clover Health Investments, Corp trades at a P/E of N/A (forward 28.7). TrendMatrix value score: 7.6/10. Verdict: Sell.

What do analysts say about CLOV?

10 analysts cover CLOV with a consensus score of 3.8/5. Average price target: $3.

What does Clover Health Investments, Corp do?Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred...